Int Arch Otorhinolaryngol:过敏性鼻炎患者和健康人群之间的1α-25-二羟维生素D3和lgE水平比较

2018-11-10 AlexYang MedSci原创

过敏性鼻炎是最常见的的过敏性疾病之一,并且能够引起生活质量的降低。在过去的几十年中,该疾病患者数目的增加的原因归结到了工业化和生活方式变化。维生素D是一种固醇类激素,在人体中具有显著的免疫条款和抗氧化作用。最近,有研究人员调查了1α-25-二羟维生素D3在过敏性患者中的作用,并比较了与健康人群中该物质的水平。研究总共包括了256名参与者。过敏性鼻炎通过过敏性鼻炎和对哮喘的影响(ARIA)指南来进行

过敏性鼻炎是最常见的的过敏性疾病之一,并且能够引起生活质量的降低。在过去的几十年中,该疾病患者数目的增加的原因归结到了工业化和生活方式变化。维生素D是一种固醇类激素,在人体中具有显著的免疫条款和抗氧化作用。最近,有研究人员调查了1α-25-二羟维生素D3在过敏性患者中的作用,并比较了与健康人群中该物质的水平。

研究总共包括了256名参与者。过敏性鼻炎通过过敏性鼻炎和对哮喘的影响(ARIA)指南来进行诊断,并通过皮刺试验来进行确定。研究人员对患者组和健康对照组均测量了血液样本中的1α-25-二羟维生素D3、免疫球蛋白E(lgE)和嗜酸粒细胞水平。研究发现,在过敏性鼻炎组中,1α-25-二羟维生素D3的平均血清水平为25.5±3.74,对照组平均水平为31.58±3.85。上述差异阐释了过敏性鼻炎组中其水平具有显著的降低(p<0.05)。另外,总的lgE水平在过敏性鼻炎组中显著的增加(p<0.05),并且与血清1α-25-二羟维生素D3水平呈现负相关关系(r=-0.259, p <0.05)。

最后,研究人员指出,更低的血清1α-25-二羟维生素D3水平在过敏性鼻炎组中出现。因此,研究人员认为,1α-25-二羟维生素D3的适当补充也许能够减轻过敏性鼻炎的症状和迹象,但是仍旧需要进一步的研究。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2047039, encodeId=3e73204e0392a, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri May 24 08:37:00 CST 2019, time=2019-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911125, encodeId=d9bb191112522, content=<a href='/topic/show?id=8c0d2e73196' target=_blank style='color:#2F92EE;'>#健康人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27731, encryptionId=8c0d2e73196, topicName=健康人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55f6293, createdName=lishizhe, createdTime=Mon Aug 12 10:37:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352530, encodeId=99763525303d, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Wed Nov 14 08:40:45 CST 2018, time=2018-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539213, encodeId=94b715392133d, content=<a href='/topic/show?id=6505108534a' target=_blank style='color:#2F92EE;'>#lgE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10853, encryptionId=6505108534a, topicName=lgE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=beb613117181, createdName=HNYYM, createdTime=Mon Nov 12 03:37:00 CST 2018, time=2018-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352171, encodeId=7cfe3521e113, content=学习了,涨知识了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDM9swhbgTo7nzqRKzMmzckmEoeTyLQVDCgjqsicjyhxPs0vPoYU6GsSYbCjSkNHicJkz3NL0a0EbUMVdNjkctXI6FocpGKaVr9E/0, createdBy=29392048316, createdName=王秀, createdTime=Sat Nov 10 13:37:46 CST 2018, time=2018-11-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2047039, encodeId=3e73204e0392a, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri May 24 08:37:00 CST 2019, time=2019-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911125, encodeId=d9bb191112522, content=<a href='/topic/show?id=8c0d2e73196' target=_blank style='color:#2F92EE;'>#健康人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27731, encryptionId=8c0d2e73196, topicName=健康人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55f6293, createdName=lishizhe, createdTime=Mon Aug 12 10:37:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352530, encodeId=99763525303d, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Wed Nov 14 08:40:45 CST 2018, time=2018-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539213, encodeId=94b715392133d, content=<a href='/topic/show?id=6505108534a' target=_blank style='color:#2F92EE;'>#lgE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10853, encryptionId=6505108534a, topicName=lgE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=beb613117181, createdName=HNYYM, createdTime=Mon Nov 12 03:37:00 CST 2018, time=2018-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352171, encodeId=7cfe3521e113, content=学习了,涨知识了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDM9swhbgTo7nzqRKzMmzckmEoeTyLQVDCgjqsicjyhxPs0vPoYU6GsSYbCjSkNHicJkz3NL0a0EbUMVdNjkctXI6FocpGKaVr9E/0, createdBy=29392048316, createdName=王秀, createdTime=Sat Nov 10 13:37:46 CST 2018, time=2018-11-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2047039, encodeId=3e73204e0392a, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri May 24 08:37:00 CST 2019, time=2019-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911125, encodeId=d9bb191112522, content=<a href='/topic/show?id=8c0d2e73196' target=_blank style='color:#2F92EE;'>#健康人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27731, encryptionId=8c0d2e73196, topicName=健康人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55f6293, createdName=lishizhe, createdTime=Mon Aug 12 10:37:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352530, encodeId=99763525303d, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Wed Nov 14 08:40:45 CST 2018, time=2018-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539213, encodeId=94b715392133d, content=<a href='/topic/show?id=6505108534a' target=_blank style='color:#2F92EE;'>#lgE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10853, encryptionId=6505108534a, topicName=lgE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=beb613117181, createdName=HNYYM, createdTime=Mon Nov 12 03:37:00 CST 2018, time=2018-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352171, encodeId=7cfe3521e113, content=学习了,涨知识了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDM9swhbgTo7nzqRKzMmzckmEoeTyLQVDCgjqsicjyhxPs0vPoYU6GsSYbCjSkNHicJkz3NL0a0EbUMVdNjkctXI6FocpGKaVr9E/0, createdBy=29392048316, createdName=王秀, createdTime=Sat Nov 10 13:37:46 CST 2018, time=2018-11-10, status=1, ipAttribution=)]
    2018-11-14 一天没事干

    很好的学习机会

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2047039, encodeId=3e73204e0392a, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri May 24 08:37:00 CST 2019, time=2019-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911125, encodeId=d9bb191112522, content=<a href='/topic/show?id=8c0d2e73196' target=_blank style='color:#2F92EE;'>#健康人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27731, encryptionId=8c0d2e73196, topicName=健康人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55f6293, createdName=lishizhe, createdTime=Mon Aug 12 10:37:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352530, encodeId=99763525303d, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Wed Nov 14 08:40:45 CST 2018, time=2018-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539213, encodeId=94b715392133d, content=<a href='/topic/show?id=6505108534a' target=_blank style='color:#2F92EE;'>#lgE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10853, encryptionId=6505108534a, topicName=lgE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=beb613117181, createdName=HNYYM, createdTime=Mon Nov 12 03:37:00 CST 2018, time=2018-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352171, encodeId=7cfe3521e113, content=学习了,涨知识了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDM9swhbgTo7nzqRKzMmzckmEoeTyLQVDCgjqsicjyhxPs0vPoYU6GsSYbCjSkNHicJkz3NL0a0EbUMVdNjkctXI6FocpGKaVr9E/0, createdBy=29392048316, createdName=王秀, createdTime=Sat Nov 10 13:37:46 CST 2018, time=2018-11-10, status=1, ipAttribution=)]
    2018-11-12 HNYYM
  5. [GetPortalCommentsPageByObjectIdResponse(id=2047039, encodeId=3e73204e0392a, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri May 24 08:37:00 CST 2019, time=2019-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911125, encodeId=d9bb191112522, content=<a href='/topic/show?id=8c0d2e73196' target=_blank style='color:#2F92EE;'>#健康人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27731, encryptionId=8c0d2e73196, topicName=健康人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55f6293, createdName=lishizhe, createdTime=Mon Aug 12 10:37:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352530, encodeId=99763525303d, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Wed Nov 14 08:40:45 CST 2018, time=2018-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539213, encodeId=94b715392133d, content=<a href='/topic/show?id=6505108534a' target=_blank style='color:#2F92EE;'>#lgE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10853, encryptionId=6505108534a, topicName=lgE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=beb613117181, createdName=HNYYM, createdTime=Mon Nov 12 03:37:00 CST 2018, time=2018-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352171, encodeId=7cfe3521e113, content=学习了,涨知识了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDM9swhbgTo7nzqRKzMmzckmEoeTyLQVDCgjqsicjyhxPs0vPoYU6GsSYbCjSkNHicJkz3NL0a0EbUMVdNjkctXI6FocpGKaVr9E/0, createdBy=29392048316, createdName=王秀, createdTime=Sat Nov 10 13:37:46 CST 2018, time=2018-11-10, status=1, ipAttribution=)]
    2018-11-10 王秀

    学习了,涨知识了!

    0

相关资讯

儿童过敏性鼻炎,应该如何用药?

随着生活环境的变化,过敏性鼻炎(又称变应性鼻炎)已成为儿童的常见病和多发病。据统计,我国儿童过敏性鼻炎的患病率已高达7.83%~29.42%。过敏性鼻炎难以根治,合理用药非常重要。一、过敏鼻炎与普通感冒的简单鉴别1、病因不同:普通感冒是由病毒(其中鼻病毒约占30%~50%)引起的感染性疾病;而过敏性鼻炎是机体接触过敏原后,由IgE介导的非感染性炎性疾病。2、症状不同:普通感冒常有伴咽痛、发热和全身

Immun Inflamm Dis:永久过敏性鼻炎患者中,MP-AzeFlu治疗效果分析

大多数过敏性鼻炎(AR)患者患有中度到重度以及永久性症状。MP-AzeFlu组合鼻内盐酸氮卓斯汀(AZE)和氟替卡松丙酸酯(FP)可以作为一种新的治疗方法来治疗AR。最近,有研究人员在一个前瞻性的和非介入性研究中探索和评估了MP-AzeFlu在减轻AR症状严重度中的效果。研究人员发现,那些使用MP-AzeFlu的患者的VAS评分从开始的73.4mm(SD.20.3)快速降低到了第28天的31.5m

Allergy:青少年到成年人群体中,过敏性鼻炎预测因子分析

虽然儿童的遗传性过敏疾病已经了解很短哦,但是从儿童到成年人中,遗传过敏性疾病的持久性相关知识却非常有限。最近,有研究人员在一个非选择性青少年群体中研究了遗传过敏性疾病和I型敏感症的临床特点,并跟踪调查到成年人阶段。研究人员发现,遗传过敏性疾病的流行度高,并且从青少年(31%)到成年人(57%)过程中具有显著的增加,尤其是过敏性鼻炎,发生率增加的幅度为17.5/1000人/年。成年过敏性鼻炎的儿童时

Int Forum Allergy Rhinol:儿童中过敏性鼻炎和夜尿症相关风险研究

尽管有争论,过敏和夜尿症(NE)之间的相关性在近一个世纪里均有报道。过敏性鼻炎(AR)相关的睡眠障碍呼吸经常导致睡眠的微觉醒,从而减少了睡眠的质量,改变了睡眠模式和行为。NE是儿童中一种常见的睡眠障碍。因此,有研究人员调查了AR儿童的NE发生和风险情况。研究是一个基于群体的研究,包括了327928名患有AR的儿童和327601名不患有AR的对照儿童。时间为2012年,地点为中国台湾到2012年。研

Ann Allergy Asthma Immunol:奥洛帕他定/莫米松组合鼻用喷雾能够改善季节过敏性鼻炎症状

GSP301鼻用喷雾是抗组胺药物盐酸奥洛帕他定和皮质类固醇糠酸莫米他松的固定剂量组合,并倾向性的用于季节过敏性鼻炎(SAR)的治疗。最近,有研究人员在一个豚草花粉环境暴露环境(EEC)下,评估了一日一次(QD)或者一日二次(BID)下的效果和安全性。研究是一个随机的、双盲的和双模拟研究,研究人员将SAR患者(年龄在18-65岁)随机等分到GSP301 BID组、GSP301 QD组、AzeFlu组

盘点:鼻炎研究进展

鼻炎即鼻腔炎性疾病,是病毒、细菌、变应原、各种理化因子以及某些全身性疾病引起的鼻腔黏膜的炎症。鼻炎的主要病理改变是鼻腔黏膜充血、肿胀、渗出、增生、萎缩或坏死等。梅斯医学小编整理了近期过敏性鼻炎的研究进展,与大家一起分享学习!【1】J Agromedicine:美国农场经营者农药的使用、过敏性鼻炎和哮喘情况分析 最近,有研究人员在美国农场经营者中调查了特殊农药的使用与过敏性鼻炎以及哮喘